Investors Event Calendar
View recent presentations and learn more about upcoming events.
Sandoz Capital Markets Day
June 08, 2023 - New York, USA
June 12, 2023 - London, UK
First quarter results 2023
April 25, 2023 | Basel, Switzerland
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
Condensed financial report (PDF 0.3 MB)
Download the podcast (MP3 34 MB)
Download the interactive presentation (PDF 3.4 MB)
Read the presentation transcript
Novartis Q1 2023 Impact and Sustainability Update (PDF 1.9 MB)
Environmental, Social and Governance (ESG)
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.
ESG Updates: May 03, 2023 (PDF 1.9 MB) | Feb 06, 2023 (PDF 0.9 MB) | Oct 31, 2022 (PDF 0.5 MB) | July 20, 2022 (PDF 0.4 MB)
Latest updates: Investor Update on Access & Sustainability (PDF 1.6 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Novartis Annual Reporting Suite
Read and download our integrated report, annual regulatory filings, and other disclosures.
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
CH-4056 Basel, Switzerland